Mesoblast News, Mesoblast Quote, MESO Quote

Mesoblast (NQ:MESO) Delayed: 6.12 -0.1 (1.61%)

Prev. Close

$6.22

Open

$6.13

52 Wk High

$10.89

52 Wk Low

$3.50

Day High

$6.28

Day Low

$5.90

P/E

N/A

EPS

$0.00

Volume

152,608

Friends, Peers and Foes (?): MSB, MSB:AU COYA (more...)

Mar 26, 2024 05:28 AM Mesoblast (MESO) Notified by FDA that Available Data from Phase 3 Trial Appear Sufficient to Support BLA Submission
Mar 25, 2024 10:34 PM United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Ste
Mar 13, 2024 07:30 PM Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
Mar 10, 2024 07:55 PM Mesoblast (MSB) FDA Supports Accelerated Approval Pathway for Rexlemestrocel-L
Mar 10, 2024 07:54 PM United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
Feb 28, 2024 05:57 PM Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
Feb 15, 2024 03:54 AM Mesoblast Limited (MESO) Announces FDA Granted Orphan-Drug Designation for Revascor
Feb 14, 2024 07:46 PM United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
Jan 30, 2024 09:13 PM Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
Jan 19, 2024 04:50 AM Mesoblast (MESO) Granted FDA Rare Pediatric Disease Designation for Revascor

Entities mentioned with MESO